Personalis Stock Forecast, Price & News

Personalis' stock was trading at $6.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PSNL stock has increased by 361.3% and is now trading at $27.77.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Personalis in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Personalis.

Wall Street analysts have given Personalis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Personalis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Personalis is scheduled to release its next quarterly earnings announcement on Wednesday, March 24th 2021.
View our earnings forecast for Personalis.

Personalis, Inc. (NASDAQ:PSNL) issued its earnings results on Thursday, November, 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.29) by $0.02. The company earned $19.82 million during the quarter, compared to analysts' expectations of $19.25 million. Personalis had a negative net margin of 43.16% and a negative return on equity of 31.11%.
View Personalis' earnings history.

7 analysts have issued 12 month price objectives for Personalis' shares. Their forecasts range from $24.00 to $35.00. On average, they expect Personalis' stock price to reach $31.14 in the next twelve months. This suggests a possible upside of 12.1% from the stock's current price.
View analysts' price targets for Personalis.

Personalis saw a increase in short interest in October. As of October 30th, there was short interest totaling 1,670,000 shares, an increase of 14.4% from the October 15th total of 1,460,000 shares. Based on an average daily trading volume, of 690,300 shares, the days-to-cover ratio is presently 2.4 days. Approximately 7.1% of the shares of the stock are sold short.
View Personalis' Short Interest.

Some companies that are related to Personalis include Veracyte (VCYT), Burning Rock Biotech (BNR), CareDx (CDNA), Genetron (GTH), RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Renalytix AI (RNLX), DermTech (DMTK), Centogene (CNTG), Exagen (XGN), Progenity (PROG), Celcuity (CELC), Enzo Biochem (ENZ) and AnPac Bio-Medical Science (ANPC).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Personalis investors own include Enphase Energy (ENPH), Pfizer (PFE), Dynavax Technologies (DVAX), QUALCOMM (QCOM), Advanced Micro Devices (AMD), NIO (NIO), NVIDIA (NVDA), Viking Therapeutics (VKTX), AbbVie (ABBV) and Aphria (APHA).

(PSNL) raised $100 million in an IPO on Thursday, June 20th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen and Company acted as the underwriters for the IPO and Oppenheimer was co-manager.

Personalis trades on the NASDAQ under the ticker symbol "PSNL."

Personalis' stock is owned by a variety of institutional and retail investors. Top institutional investors include Abingworth LLP (11.46%), JPMorgan Chase & Co. (9.29%), ARK Investment Management LLC (10.33%), BlackRock Inc. (6.55%), Nikko Asset Management Americas Inc. (2.89%) and Candriam Luxembourg S.C.A. (1.59%). Company insiders that own Personalis stock include Aaron Tachibana, Ken Ludlum, Lightspeed Venture Partners Se, Llp Abingworth and Richard Chen.
View institutional ownership trends for Personalis.

PSNL stock was sold by a variety of institutional investors in the last quarter, including Abingworth LLP, Gabelli Funds LLC, Cadence Capital Management LLC, Candriam Luxembourg S.C.A., Los Angeles Capital Management & Equity Research Inc., and Wells Fargo & Company MN. Company insiders that have sold Personalis company stock in the last year include Aaron Tachibana, Ken Ludlum, Llp Abingworth, and Richard Chen.
View insider buying and selling activity for Personalis.

PSNL stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., ARK Investment Management LLC, BlackRock Inc., Federated Hermes Inc., Nikko Asset Management Americas Inc., Voloridge Investment Management LLC, Cubist Systematic Strategies LLC, and Charles Schwab Investment Management Inc.. Company insiders that have bought Personalis stock in the last two years include Ken Ludlum, and Lightspeed Venture Partners Se.
View insider buying and selling activity for Personalis.

Shares of PSNL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PSNL stock can currently be purchased for approximately $27.77.

Personalis has a market capitalization of $1.08 billion and generates $65.21 million in revenue each year. The company earns $-25,080,000.00 in net income (profit) each year or ($1.39) on an earnings per share basis. Personalis employs 181 workers across the globe.

The official website for Personalis is www.personalis.com.

Personalis' mailing address is 1330 O`BRIEN DRIVE, MENLO PARK CA, 94025. The company can be reached via phone at 650-752-1300 or via email at [email protected]